Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Income from Continuing Operations: 2011-2025

Historic Income from Continuing Operations for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$623,000.

  • Fennec Pharmaceuticals' Income from Continuing Operations rose 89.09% to -$623,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 588.35%. This contributed to the annual value of -$436,000 for FY2024, which is 97.28% up from last year.
  • Fennec Pharmaceuticals' Income from Continuing Operations amounted to -$623,000 in Q3 2025, which was up 80.25% from -$3.2 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Income from Continuing Operations ranged from a high of $12.9 million in Q1 2024 and a low of -$10.3 million during Q4 2022.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$2.6 million (2023), whereas its average is -$1.9 million.
  • Examining YoY changes over the last 5 years, Fennec Pharmaceuticals' Income from Continuing Operations showed a top increase of 316.58% in 2024 and a maximum decrease of 222.47% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Income from Continuing Operations stood at -$4.2 million in 2021, then crashed by 89.66% to -$10.3 million in 2022, then soared by 74.66% to -$2.6 million in 2023, then spiked by 42.67% to -$1.5 million in 2024, then soared by 89.09% to -$623,000 in 2025.
  • Its Income from Continuing Operations stands at -$623,000 for Q3 2025, versus -$3.2 million for Q2 2025 and -$1.2 million for Q1 2025.